Vertaling van "has now been successfully " (Nederlands → Frans) :

Pantoloc Control, the PPI licensed throughout Europe in early 2010, has now been successfully launched as expected in all 14 European markets targeted.
Pantoloc Control, l’IPP dont Novartis a obtenu la licence pour l’Europe début 2010, a été lancé avec succès comme prévu dans les quatorze marchés européens ciblés.

Aclasta/Reclast (USD 254 million), the first once-yearly infusion therapy for various forms of osteoporosis, has now been used in more than 350,000 patients and has experienced consistent growth since its launch to treat postmenopausal osteoporosis in late 2007.
Aclasta/Reclast (USD 254 millions), première injection annuelle pour soigner différentes formes d’ostéoporose, a été utilisé par plus de 350 000 patients et a affiché une croissance notable depuis son lancement, à fin 2007, pour le traitement de l’ostéoporose potsménopausique.

This biotechnology eye therapy, which is approved in more than 80 countries for “wet” age-related macular degeneration, has now been used in more than 250,000 patients for this disease, a leading cause of blindness in people over age 50.
Ce traitement oculaire issu des biotechnologies, autorisé dans plus de 80 pays contre la forme exsudative de la dégénérescence maculaire liée à l'âge, cause principale de cécité chez les personnes âgées de plus de 50 ans, a été utilisé chez plus de 250 000 malades.

The business portfolio has been successfully transformed to focus on healthcare, the research organization is highly respected and the pipeline is full and highly valued.
Le portefeuille d’activités a été transformé avec succès pour se focaliser sur les soins de santé, l’organisation de recherche est éminemment respectée, tandis que le pipeline est plein et hautement considéré.

Novartis has now largely finished deliveries of A (H1N1) pandemic vaccines and adjuvants to fulfill agreements with various governments, including the United States, following the pandemic outbreak in mid-2009, and production of A (H1N1) monovalent doses has been stopped.
Novartis a largement achevé les livraisons de vaccins contre la pandémie de grippe A (H1N1) et d’adjuvants conformément aux accords conclus avec différents gouvernements, dont les Etats-Unis, à la suite du déclenchement de la pandémie à la mi-2009. La production des doses monovalentes de A (H1N1) a été stoppée.

The US government has now awarded Novartis two contracts totaling USD 979 million for future purchase of H1N1 bulk vaccine and the Group’s proprietary MF59 adjuvant, while contracts have also been received from other countries.
Le gouvernement américain a accordé à Novartis deux contrats totalisant USD 979 millions pour l’achat futur du vaccin H1N1 en masse et de l’adjuvant MF59 propriété du Groupe, tandis que des contrats ont également été conclus avec d’autres pays.

Each report of an adverse effect is now processed in two phases. For the first phase “preparing” the electronic report approximately 60 % of the backlog has been removed.
Each report of an adverse effect is now processed in two phases. For the first phase “preparing” the electronic report approximately 60 % of the backlog has been removed.

At present there are five agents who belong to the internal FAMHP team and ten agents who are supplied by the ICT service of the FPS Public Health, with which an SLA has been concluded in order to bring to a successful conclusion the transfer of tools and IT skills from the former DG Medicinal Products to the FAMHP and ensure the continuity of service provision.
At present there are five agents who belong to the internal FAMHP team and ten agents who are supplied by the ICT service of the FPS Public Health, with which an SLA has been concluded in order to bring to a successful conclusion the transfer of tools and IT skills from the former DG Medicinal Products to the FAMHP and ensure the continuity of service provision.

The provision of scientific advice at the level of the EMEA has been a particular success in recent years.
The provision of scientific advice at the level of the EMEA has been a particular success in recent years.

Achieving success with long-term R&D investments Novartis has been reaping the benefits of long-term, disciplined investments in innovation, achieving more than 30 major regulatory approvals and significant progress in the Group’s R&D pipeline so far in 2009.
Succès des investissements à long terme dans la R&D Novartis a récolté les fruits d'investissements judicieux à long terme dans l'innovation. Il a en effet obtenu plus de 30 autorisations majeures de mise sur le marché et réalisé à ce jour en 2009 d’importants progrès dans le pipeline de R&D du Groupe.